# ImmuneOnco Biopharmaceuticals (Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immuneonco-biopharmaceuticals-shanghai-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.immuneonco.com
- Total disclosed funding: $130M
- Latest round: Series C (Mar 24, 2021)
- Investors on record: 11

## About

Based in Shanghai, China and founded in 2015, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. operates as a biopharmaceutical company that develops novel immunotherapy for patients with cancer. The company was founded by its CEO Wenzhi Tian. In March 2021, ImmuneOnco Biopharmaceuticals raised USD 89 million in series C funding from Greater Bay Area Homeland Investments Limited, Lilly Asia Ventures, and Lyfe Capital.

ImmuneOnco Biopharmaceuticals focuses on the development and research of anti-tumor immunotherapy products such as bispecific antibodies and new recombinant proteins. The company also provides Target-Activated NK (TANK™) Cell Therapy and Macrophages which help to detect and kill target cancer cells.

Following the funding in 2021, the company plans to use the investment for clinical program and drug development and factory construction.

## Funding rounds

- Series C, Mar 24, 2021, $89M — Lilly Asia Ventures, Shanghai International Group, LYFE Capital, Shanghai Zhangke Lingyi Investment Management Co., LTD, Greater Bay Area Homeland Investments Limited
- Series B, Oct 11, 2020, $25M — Lilly Asia Ventures, LYFE Capital, Milestone Asset Management
- Series A, Apr 11, 2018, $16M — Z&H Investment, Langsheng Investment, Milestone Asset Management, Biossom Investment Management, Beijing Longpan Investment Management Consulting Center, Yaluo Investment

## Investors

- Z&H Investment (https://capitalatlas.ai/funds/z-h-investment) — Series A
- Langsheng Investment (https://capitalatlas.ai/funds/langsheng-investment) — Series A
- Milestone Asset Management — Series A, Series B
- Biossom Investment Management (https://capitalatlas.ai/funds/biossom-investment-management) — Series A
- Beijing Longpan Investment Management Consulting Center — Series A
- Yaluo Investment — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B, Series C
- LYFE Capital — Series B, Series C
- Shanghai International Group — Series C
- Shanghai Zhangke Lingyi Investment Management Co., LTD — Series C
- Greater Bay Area Homeland Investments Limited (https://capitalatlas.ai/funds/greater-bay-area-homeland-investments-limited) — Series C